OMass Therapeutics
Generated by Meeveem AI
"Discovering medicines against validated membrane protein targets in immunology and rare diseases"
Oxford
•51 - 250 Employees
•Biotechnology
About OMass Therapeutics
OMass Therapeutics develops small molecule drugs targeting membrane proteins and intracellular complexes that conventional methods struggle to address. Using proprietary biochemistry and native mass spectrometry, the company studies targets within their biological ecosystems, preserving the physical interactions that drive function. This bridges cell-based biological relevance with cell-free precision. The platform discovers drugs against solute carriers, GPCRs, and inflammasome complexes for orphan diseases and immunological conditions. By maintaining protein partners, lipid interactions, and regulatory molecules while measuring binding precisely, OMass finds therapeutic opportunities standard assays miss. Programmes target rare endocrine disorders, lupus, and inflammatory bowel disease.
78
Team Members
2016
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where difficult-to-drug membrane proteins and intracellular complexes become accessible therapeutic targets, enabling effective treatments for patients with rare diseases and immunological conditions who currently have limited options.
Our Mission
At OMass Therapeutics, our mission is to discover, develop and deliver impactful medicines that transform the lives of patients with rare diseases and immunological conditions.